Fortrea's Upcoming Financial Results Announcement
Fortrea, a prominent global contract research organization (CRO), is gearing up to announce its financial performance for the third quarter of 2024. The company plans to release its financial results before the market opens on a designated Friday in November. In conjunction with the results announcement, Fortrea will host a conference call designed to provide insights into its financial performance.
Key Details of the Conference Call
The conference call is set to take place at 8:00 am ET on the same day that the financial results are unveiled. Participants interested in joining this discussion are encouraged to register online on the Fortrea Investor Relations website well in advance. This proactive approach will help ensure a smooth experience, minimizing potential delays before the call begins.
Accessing the Live Conference
Individuals who wish to listen in on the conference call can do so through an earnings webcast link provided by Fortrea. This live platform will facilitate real-time interaction, allowing stakeholders to grasp the company’s performance and respond to inquiries during the question-and-answer segment. Post-event, a recorded version of the session will be accessible for further review, catering to those unable to attend live.
Fortrea: A Leader in Clinical Development Solutions
Fortrea stands out as a leading provider of clinical development solutions in the life sciences sector. The company collaborates with a range of clients, including up-and-coming biopharmaceuticals and established biotechnology firms, to advance healthcare innovations that expedite the delivery of transformative therapies to patients. Fortrea specializes in managing clinical trials across all phases—ranging from phase I to IV—and offers critical consulting services.
Experience and Reach of Fortrea
With decades of expertise across more than 20 therapeutic areas, Fortrea boasts a reputation for scientific rigor and insightful analysis. Its extensive investigator site network is a vital asset, enhancing the company's capability to offer agile solutions tailored to client needs. Employing a diverse workforce in nearly 100 countries, Fortrea is well-equipped to respond to global market demands while maintaining a focus on comprehensive support for its clients.
Innovative Solutions and Collaborations
Fortrea continues to evolve by adopting innovative solutions and strategic partnerships that foster advancements in clinical research. By prioritizing collaboration with biopharmaceutical companies and medical technology firms, Fortrea drives improvements in clinical trial processes and outcomes, ultimately benefiting patients who rely on cutting-edge therapies.
Contacting Fortrea for More Information
For inquiries, Fortrea provides multiple channels of communication. Investors and media representatives can reach out to dedicated contact points. Hima Inguva handles investor-related questions, while Sue Zaranek and Kate Dillon are available for media inquiries. This organized structure ensures that stakeholders receive timely responses and support as needed.
Frequently Asked Questions
What are the key details of Fortrea's financial results announcement?
Fortrea will announce its third quarter 2024 financial results before the market opens on a Friday in November, followed by a conference call.
How can I participate in the Fortrea conference call?
Participants can register online at the Fortrea Investor Relations website and are recommended to join at least 10 minutes before the call starts.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be accessible shortly after the live event concludes on the Fortrea Investor Relations website.
What services does Fortrea provide?
Fortrea is a leading provider of clinical development solutions, specializing in managing clinical trials and offering consulting services for life sciences.
Who can I contact for more information about Fortrea?
For investor inquiries, contact Hima Inguva at 877-495-0816, and for media inquiries, reach out to Sue Zaranek or Kate Dillon through the provided email addresses.
